40 Years of Making Quality Healthcare Affordable-Symposium 21-11-2012

Category: Others/ Misc

Presentation Description

On the 21st November 2012, it was 40 years since a group of pharmacy students decided to set up IDA Foundation, with the mission of improving access to high-quality essential medicines and medical supplies at the lowest possible price to low- and medium-income countries. To celebrate this anniversary, our organisation had several events lined up. Aside from celebrating this achievement with our Dutch and Indian colleagues, who visited our headquarters in Amsterdam, we organised a symposium on Wednesday 21st November in the Royal Tropical Institute in Amsterdam. Over 100 partners, suppliers and customers joined us for a morning of reflecting on “40 Years of Making Quality Healthcare Affordable”, with presentations by our customers and partners, as well as our director. In the afternoon, the programme became more interactive, with a lively debating session organised by the Dutch Debate Institute. All participants took position on motions relating to quality assurance, pricing of essential medicines and patents. After a long day, we were able to relax and catch up with our international guests at the reception. We look back on a great week and look forward to hopefully 40 more successful years to come!


Presentation Transcript

Looking back at IDA’s 40th Anniversary Symposium Royal Tropical Institute (KIT), Amsterdam:

Looking back at IDA’s 40 th Anniversary Symposium Royal Tropical Institute (KIT), Amsterdam 21 st November 2012

Symposium: Opening of Morning Session:

Symposium: Opening of Morning Session Opening of the symposium by Dr. Hans Hogerzeil , former Director of Quality at WHO. He introduced the various speakers of the morning programme, which focused on reflecting on IDA’s partnerships over the past 40 years.

Welcome, by Edwin de Voogd:

Welcome, by Edwin de Voogd Edwin de Voogd, Managing Director of IDA Foundation, looked back at when he joined IDA (2007), wondering whether our mission was still relevant. Reflecting on a trip to Western Africa, he saw first hand that IDA’s work was still relevant – AND necessary. He concluded that YES  IDA’s mission is relevant …BUT we are not there yet Our focus for the future is achieving what companies such as Coca Cola, Wrigley’s and Apple have already done; reaching all corners of the world. Therefore IDA will focus on ‘Ensuring availability - there where it is needed’

Reflecting on IDA’s rich history :

Reflecting on IDA’s rich history IDA Sales & Marketing Manager Hans Vollebregt read Mr. Shree Rajwade’s story of how IDA Foundation opened an office in Mumbai, India in 2006. Mr.Rajwade has been the general manager of our Mumbai office since the beginning. Advisory Board member Wilbert Bannenberg spoke about the early years of IDA and how the organisation has professionalised over the years. He also identified the changes within the industry and how IDA can adapt to the changing landscape. Patents on medicines pose a challenge More competition is also a good thing: essential drugs concept is well developed Rise of non-communicable diseases vs. ATM Our mission is relevant to neglected diseases and dosage forms (paediatric drugs)

Celebrating Partnership: Partners in Health:

Celebrating Partnership: Partners in Health Kathryn Kempton, Director of International Operations spoke about the longstanding relationship between IDA and Partners in Health. Like IDA, PiH has grown from a small organisation of passionate volunteers to a large, international organisation, working on projects throughout the world. After her presentation, she introduced a special message recorded by Dr. Paul Farmer, founder of Partners in Health. To see his message, click on the link below: Message from Paul Farmer (click on link for video)

GDF – IDA Foundation: Partners in the supply of TB medicines:

GDF – IDA Foundation: Partners in the supply of TB medicines Upscale schedule for second-line TB medicines is ambitious. However, if funding is assured, targets can be reached by focusing on: Solid global forecasting Manufacturing capacity Local capacity building Dr. Kaspars Lunte, Team Leader MDR-TB medicines supply for GDF (WHO) spoke of the challenges faced by GDF in the supply of (2 nd line) TB medicines. Looking ahead he emphasised the value of the IDA-GDF partnership and that in the coming years we will not only supply 2 nd line, but 1 st line TB drugs as well.

A customer’s perspective: CHAN Medi-Pharm:

A customer’s perspective: CHAN Medi-Pharm Mr. Matthew Azoji, CEO of CHAN Medi-Pharm spoke about the main pillars of our joint work in Nigeria. CHAN and IDA already started their cooperation in 1979! Through partnership, we were able to build the IDA brand in Nigeria Quality of medicines is key in a country where focus is not always on quality And an advice to IDA: don’t forget the increasing menace of non-communicable diseases

The afternoon sessions: debates!:

The afternoon sessions: debates! Donatello Piras, from the Dutch Debate Institute, explains the rules of the game: We will debate 3 motions Each motion will be introduced by an expert The jury will decide which group comes up with the strongest arguments The motions: All antiretrovirals should be licensed to the Medicines Patent Pool The quality assurance system of wholesalers should be abolished The pharmaceutical industry should determine medicine prices

Talking about patents…:

Talking about patents… By comparing the medicines market with the airplane market in its early days, Ellen ‘t Hoen made the complex world of intellectual property rights much easier. Ellen is the former MD of the Medicines Patent Pool. After fierce debates, the larger part of the audience agrees to the motion: Indeed, all ARV’s should be licensed to the Medicines Patent Pool.

And is a QA system for wholesalers really necessary?:

And is a QA system for wholesalers really necessary? Dr. Hans Hogerzeil looks back at why WHO ever started its prequalification Programme. QA is necessary for the mere reason that suppliers will give you quality A if they know you are testing, and quality B if they know you are not…. And the audience agrees: Yes, a quality assurance system for wholesalers is necessary. However: We should at all times try to avoid duplication We should work towards improving the National Drug Regulating Authorities in order for them to be able to take responsibility

And why should manufacturers not determine their own prices?:

And why should manufacturers not determine their own prices? Dr. Joep Lange, founder of the Amsterdam Institute of Global Health and Development (AIGHD), gives some arguments in favor and against manufacturers setting their own prices. And he underlines the role of activists. They played a very important role in bringing ARV prices down… We reach consensus: for branded industry and monopolist markets, regulation is necessary. Generic manufacturers on the other side, should be able to determine their own prices.

Looking forward to the future of IDA:

Looking forward to the future of IDA “The middle of the pyramid would be a segment where IDA could add value: those patients able to pay a small amount for their medicines, however not the full price. Think about health insurance systems!” “IDA can focus on “other” essential medicines: mother & child health, pediatric medicines, non-communicable diseases” “IDA has an opportunity to engage the private sector: the traditional Central Medical Store system in many low- and medium income countries is changing and private sector’s role will be increasingly important” We reflected on the main points discussed during the day: “Our 40 years history shows we have achievements to be proud of, but there is still a lot of work to be done. We will continue to focus on ensuring availability of medicines – there where it is needed”

It was a day full of fruitful discussions:

It was a day full of fruitful discussions THANK YOU TO ALL PARTICIPANTS!!!

authorStream Live Help